KG LEGAL \ INFO
BLOG

KIELTYKA GLADKOWSKI KG LEGAL TAKES PART IN CYBERSECURITY WEBINAR ORGNAISED BY THE WALL STREET JOURNAL

KIELTYKA GLADKOWSKI KG LEGAL will take part in the cybersecurity webinar organized on 14 April 2022 by the Wall Street Journal.

The areas explored will be the effect on the existing and new privacy regulations on companies doing business internationally (data transfers between the US and Europe); the effect of global changes to privacy regulations on U.S. companies and consumers; new technologies that regulators and privacy officers need to be aware of.

The webinar will be moderated by David Uberti– Cybersecurity Reporter and David Breg– Deputy Research Director.

Link to the event: https://cyberwebinars.wsj.com/

More

KIELTYKA GLADKOWSKI KG LEGAL TAKES PART IN CODE TO CLOUD VIRTUAL SUMMIT

On 23 March and 24 March 2022 KIELTYKA GLADKOWSKI KG LEGAL will take part in a virtual summit Code to Cloud organized by Palo Alto Networks.

Code to Cloud is dedicated to covering security best practices across cloud native tech stacks and the development lifecycle—from IaC and open source packages to containers and workloads.

The speakers in a number of sessions will cover some key tips for integrating DevOps and security practices, as well as some of the latest research on the state of software security, showing why it is so important to make security efficient and collaborative. The speakers will talk about patterns, technologies, and approaches to evolve systems while minimizing the erosion of security practices. There will be explored the solution with HashiCorp Terraform, Consul, Vault, and Boundary, and patterns how to broadly apply them to one’s system architecture. This talk will be useful to platform, infrastructure, or security architects, and anyone designing or engineering infrastructure systems.

More

KIELTYKA GLADKOWSKI KG LEGAL TAKES PART IN ABI WEBINAR ON THE IMPACT OF THE CONFLICT IN UKRAINE ON CAPITAL, MARKETS AND BOARDROOMS

KIELTYKA GLADKOWSKI KG LEGAL takes part in the webinar organized by the American Bankruptcy Institute on the impact of the conflict in Ukraine on capital, markets and boardrooms. ABI and a panel of experts, including former U.S. House Speaker John Boehner, Former Ambassador Matthew Kirk and Former Career Ambassador Frank Wisner, will discuss the conflict in Europe, which has generated a maze of rapid legal, political and economic responses from authorities around the globe. Those actions are rippling through capital, markets and boardrooms as businesses grapple with how to respond.

More

USA IS ENSURING RESPONSIBLE DEVELOPMENT OF DIGITAL ASSETS

On Wednesday, March 9, U.S. President signed an executive order – a directive through which he manages the federal government’s activities. The decree was dedicated to the problem of digital asset development. The government administration was required to develop a strategy to better understand the risks and opportunities posed by digital assets. With this executive order, the White House directed the Departments of Treasury, Commerce, State and Justice, among others, to examine elements of the rapidly growing cryptocurrency market. The government agencies will review the market over the next six months and prepare a public report with recommendations for the federal government’s approach to digital currencies.

More

KIELTYKA GLADKOWSKI KG LEGAL PARTICIPATES IN THE MEETING OF LIFE SCIENCE CLUSTER IN COLLABORATION WITH THE JAGIELLONIAN CENTRE FOR EXPERIMENTAL THERAPEUTICS

On 30 March 2022 KIELTYKA GLADKOWSKI KG LEGAL will participate in the meeting organized by the Polish Life Science Cluster with the Jagiellonian Center for Drug Development (JCET). It is a unit of the Jagiellonian University in Krakow that conducts research on the mechanism of action of drugs and their therapeutic and toxic effects.

At the Jagiellonian Center for Drug Development there are carried out studies of the preclinical phase, i.e. laboratory work without the participation of patients. Particular emphasis is placed on understanding where side effects of drugs come from and how to predict them before a drug candidate reaches the first volunteers in clinical trials.

More

UP